AstraZeneca To Challenge GSK After Clinching Lupus Drug Approval
FDA Gives Green Light To Saphnelo
Executive Summary
Fears that US regulators would take issue with AstraZeneca's decision to change the endpoints of a second pivotal trial for anifrolumab were unfounded and the first-in-class type I interferon inhibitor is the first new treatment for systemic lupus erythematosus in more than 10 years.